226 related articles for article (PubMed ID: 28527392)
1. Immune-related bone marrow failure following anti-PD1 therapy.
Michot JM; Vargaftig J; Leduc C; Quere G; Burroni B; Lazarovici J; Champiat S; Ribrag V; Lambotte O
Eur J Cancer; 2017 Jul; 80():1-4. PubMed ID: 28527392
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitors in lung cancer: an update.
Sullivan K; Preeshagul I; Budman D; Seetharamu N
Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
[No Abstract] [Full Text] [Related]
3. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
4. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.
Tomita Y; Sueta D; Kakiuchi Y; Saeki S; Saruwatari K; Sakata S; Jodai T; Migiyama Y; Akaike K; Hirosako S; Fujisue K; Yamamura S; Miyazaki S; Takashio S; Izumiya Y; Nakamura K; Tsujita K; Ichiyasu H; Fujii K
Ann Oncol; 2017 Nov; 28(11):2893-2895. PubMed ID: 28651328
[No Abstract] [Full Text] [Related]
5. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
Tokumo K; Masuda T; Miyama T; Miura S; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Yoshida T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Lung Cancer; 2018 May; 119():21-24. PubMed ID: 29656748
[TBL] [Abstract][Full Text] [Related]
7. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.
Algaze SD; Park W; Harrington TJ; Mudad R
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523604
[TBL] [Abstract][Full Text] [Related]
8. A case of non-small cell lung cancer with danazol-dependent aplastic anemia induced by pembrolizumab.
Goda S; Tsuji T; Matsumoto Y; Shiotsu S; Tanaka S; Suga Y; Fujii H; Matsuyama A; Omura A; Yuba T; Takumi C; Hiraoka N
Curr Probl Cancer; 2021 Jun; 45(3):100686. PubMed ID: 33293197
[TBL] [Abstract][Full Text] [Related]
9. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Kao JC; Liao B; Markovic SN; Klein CJ; Naddaf E; Staff NP; Liewluck T; Hammack JE; Sandroni P; Finnes H; Mauermann ML
JAMA Neurol; 2017 Oct; 74(10):1216-1222. PubMed ID: 28873125
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
12. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
[TBL] [Abstract][Full Text] [Related]
13. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier A; Jeanville P; Champiat S; Lazarovici J; Voisin AL; Mateus C; Lambotte O; Annereau M; Michot JM
Eur J Cancer; 2017 Aug; 81():135-137. PubMed ID: 28624693
[No Abstract] [Full Text] [Related]
14. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
Tomelleri A; Campochiaro C; De Luca G; Cavalli G; Dagna L
Eur J Intern Med; 2018 Nov; 57():e11-e12. PubMed ID: 30076088
[No Abstract] [Full Text] [Related]
15. Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Amode R; Baroudjian B; Kowal A; Jebali M; Allayous C; Bagot M; Madjlessi N; Roux J; Viguier M; Basset Seguin N; Porcher R; Pagès C; Lebbé C
Melanoma Res; 2017 Apr; 27(2):110-115. PubMed ID: 27926587
[TBL] [Abstract][Full Text] [Related]
16. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V; Goldwasser F; Kramkimel N; Jouinot A; Huillard O; Boudou-Rouquette P; Chanal J; Arrondeau J; Franck N; Alexandre J; Blanchet B; Leroy K; Avril MF; Dupin N; Aractingi S
Invest New Drugs; 2017 Aug; 35(4):436-441. PubMed ID: 28396974
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
Prasad V; Kaestner V
Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
[TBL] [Abstract][Full Text] [Related]
20. Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent.
Teng Y; Guo R; Sun J; Jiang Y; Liu Y
Acta Oncol; 2019 Mar; 58(3):388-389. PubMed ID: 30700195
[No Abstract] [Full Text] [Related]
[Next] [New Search]